Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer

Volume: 3 Number: 2 June 22, 2017
  • Özlem Özkul
  • Hasan Morcalı
  • Bayram Kızılkaya
  • Gökhan Puşuroğlu
  • Yasemin Bakkal Temi
  • Cemil Bilir
EN

Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer

Abstract

Background: Nonsmall cell lung cancer (NSCLC) is increasingly seen in the elderly population. At the time of diagnosis, more than half of the patients are over 65 years of age.

Method: We retrospectively analyzed our hospital records. NSCLC patients treated with combination either chemotherapy or combination with radiation according to the stage.

Results: The median follow up period was 20 months and 9 (32%) patients died during this period. Patients with stage IV patients had 7.9 months median OS, patients who had locally advanced stage had 19 months median OS. Serum uric acid levels were significantly correlated with overall survival and overall response rates in locally advanced disease (HR 1.01-2.4, P=0.05 and 0.02, respectively).

Conclusion: Our results showed that combination therapy with taxanes and platinums can be effective choice for selected elderly patients and we can use serum uric acid levels as a prognostic factor who had advanced NSCLC.

Keywords

References

  1. 1- Owoniko TK,Ragin CC,Belani CP, et al.Lung cancer in elderly patients :an analysis of the surveillance ,epidemiology,and end results database .J Clin Oncol 2007;25:5570-5577.
  2. 2- Repetto L,Luciani A. Cancer treatment in elderly patients :evidence and clinical research.Recenti Prog Med 2015;106:23-7.
  3. 3- Ries LAG,Eisner MP,Kosary CL,et al: SEER Cancer Statistics Review 1975-2000
  4. 4- Perrone F,Gallo C,Gridelli C:Re:Cisplatin-based therapy for elderly patients with advanced non – small cell lung cancer:Implications of Eastern Cooperative Oncology gRoup 5592,a randomized trial.J Natl Cancer INST 94:1029-1031,2002.
  5. 5- Jatoi A,Hillman S,Stella P,et al:Should elderly non-small cell lung cancer patients be offered elderly-specific trials?Results of a pooled analysis from the North Central Cancer Treatment Group.J Clin Oncol 23:9113-9119,2005.
  6. 6- Sieger R.,M J,Zou Z,Jemal A.Cancer statistics ,2014.CA Cancer J Clin 2014;64:9-29.
  7. 7- Berghmans T,Paersmans M,Sculier JP.Prognostic factors in stage 3 non-small cell lung cancer :a review on conventional,metabolic and new biological variables.Ther Adv Med Oncol 2011;3:127-38.
  8. 8- Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ.Cancer statistics ,2007.CA Cancer J Clin 2007;57:43-66. 9- Edwards BK,Howe HL,Ries LA,et al.Annual report to the nation on the status of cancer ,1973-1999,featuring implications of age and aging on U.S cancer burden.Cancer .2002;94:2766-2792.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

-

Authors

Hasan Morcalı This is me

Bayram Kızılkaya This is me

Gökhan Puşuroğlu This is me

Yasemin Bakkal Temi This is me

Cemil Bilir This is me

Publication Date

June 22, 2017

Submission Date

June 22, 2017

Acceptance Date

June 13, 2017

Published in Issue

Year 2017 Volume: 3 Number: 2

APA
Özkul, Ö., Morcalı, H., Kızılkaya, B., Puşuroğlu, G., Temi, Y. B., & Bilir, C. (2017). Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm, 3(2), 101-104. https://izlik.org/JA82AK58LN
AMA
1.Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C. Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm. 2017;3(2):101-104. https://izlik.org/JA82AK58LN
Chicago
Özkul, Özlem, Hasan Morcalı, Bayram Kızılkaya, Gökhan Puşuroğlu, Yasemin Bakkal Temi, and Cemil Bilir. 2017. “Paclitaxel-Carboplatin Based Therapy in Elderly Patients With Non-Small Cell Lung Cancer”. Journal of Human Rhythm 3 (2): 101-4. https://izlik.org/JA82AK58LN.
EndNote
Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C (June 1, 2017) Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm 3 2 101–104.
IEEE
[1]Ö. Özkul, H. Morcalı, B. Kızılkaya, G. Puşuroğlu, Y. B. Temi, and C. Bilir, “Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer”, Journal of Human Rhythm, vol. 3, no. 2, pp. 101–104, June 2017, [Online]. Available: https://izlik.org/JA82AK58LN
ISNAD
Özkul, Özlem - Morcalı, Hasan - Kızılkaya, Bayram - Puşuroğlu, Gökhan - Temi, Yasemin Bakkal - Bilir, Cemil. “Paclitaxel-Carboplatin Based Therapy in Elderly Patients With Non-Small Cell Lung Cancer”. Journal of Human Rhythm 3/2 (June 1, 2017): 101-104. https://izlik.org/JA82AK58LN.
JAMA
1.Özkul Ö, Morcalı H, Kızılkaya B, Puşuroğlu G, Temi YB, Bilir C. Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm. 2017;3:101–104.
MLA
Özkul, Özlem, et al. “Paclitaxel-Carboplatin Based Therapy in Elderly Patients With Non-Small Cell Lung Cancer”. Journal of Human Rhythm, vol. 3, no. 2, June 2017, pp. 101-4, https://izlik.org/JA82AK58LN.
Vancouver
1.Özlem Özkul, Hasan Morcalı, Bayram Kızılkaya, Gökhan Puşuroğlu, Yasemin Bakkal Temi, Cemil Bilir. Paclitaxel-Carboplatin based therapy in elderly patients with Non-small Cell Lung Cancer. Journal of Human Rhythm [Internet]. 2017 Jun. 1;3(2):101-4. Available from: https://izlik.org/JA82AK58LN